Rohit Duggal is an experienced industry executive with specialization in establishing and advancing biotherapeutic products targeting cancer. His expertise is in cell therapy and immuno-oncology platforms that includes monoclonal antibodies in various formats for product development.
Rohit has more than 23 years of industry experience that spans cellular immunotherapy, immuno-oncology, oncolytic virotherapy, translational oncology and antiviral drug discovery.
Prior to joining TRL, Rohit was the head of R&D and site head of ONK Therapeutics Inc. Before that, Rohit led the primary lymphocyte product development program at NantKwest. At Sorrento Therapeutics he helped develop the immuno-oncology franchise that included antibodies in different formats. Rohit started his industry career at Agouron Pharmaceuticals that became part of Pfizer, where he worked on projects on antivirals and oncology from inception towards delivering clinical candidates.
Rohit obtained his Ph.D. from Texas A&M University.